ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1131

Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance

Ivars Veckalns and Anna Mihailova, Riga Stradins University, Riga, Latvia

Meeting: ACR Convergence 2021

Keywords: Decision Making, inflammatory arthritis, Interleukins, Osteoarthritis, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Title: Osteoarthritis – Clinical Poster III (1118–1134)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Inflammatory arthritis (IA) treated with disease modifying antirheumatic drugs lead to secondary osteoarthritis (OA) due to inflammation, aging, and other factors. Inflammatory arthritis can start in middle-aged adults with OA. Discrimination between these two conditions can pose a significant challenge, especially when there are no makers for inflammatory arthritis.

The aim is to clarify the importance of IL6 concentration in synovial fluid for treatment purposes.

Methods: Sixty-nine patients with symptomatic swelling of the joints were undergone aspiration of synovial fluid. All patients received intraarticular steroid injections for therapeutic purposes. Then decision about treatment was depended on the IL6 concentration level in synovial fluid. IL6 concentration was determined by immunochemical luminescence method. Patients with low IL6 concentration continued therapy as OA or secondary OA patients with physiotherapy, without DMARD escalation, but high IL6 concentration DMARD treatment was prescribed or adjusted.

Primary diagnosis was made based on classification criteria for certain diseases (RA, PsA, AS, OA), and the conclusion was based on clinical presentation, current lab results, and IL6 level in synovial fluid.

Results: Primarily 51 patients were classified as having IA (AS-1; RA-1; Undifferentiated IA-2; JIA-2; ReA-32; PsA-7; RA-6). 18 patients were classified as having OA. After IL6 analysis 36 patients were re-classified as having IA (Undifferentiated IA-1; JIA-1; ReA-24; PsA-4; RA-6) and 33 patients were re-classified as having OA. Out of these 33 OA patients, 20 patients were previously classified as having IA and 5 patients of the 36 IA patient’s group were previously classified as having OA. (Table 1). In 33 OA patients, the median IL6 concentration was 100 pg/ml (IQR 41.0 to 204.0). In 36 IA patients, the median was 2430.5 pg/ml (IQR 1277.0 to 5552.0). The Mann-Whitney U test showed a statistically significant difference (p< 0.001) between these two groups. (Figure 1). In the 20 patients, primarily diagnosed as IA and then classified as OA, the median IL6 concentration was 75.1 pg/ml (IQR 38.9 to 169.5). In the five patients, primarily diagnosed as OA and then classified as IA, the median IL6 concentration was 1800 pg/ml (IQR 1394.0 to 7738.0). In this group three patient were without any serological and genetic markers for inflammatory arthritis such as RF, anti-CCP, HLA-B27.

Conclusion: IL6 concentration in synovial fluid is different between IA and OA and may be helpful as an additional factor in the decision-making process.

Table1.jpeg”Table 1 Primary diagnosis and final diagnosis crosstabulation

Screenshot 2021-05_31 at 12.55.06.jpeg”Figure 1 IL-6 concentration comparison in OA and IA patient groups


Disclosures: I. Veckalns, None; A. Mihailova, None.

To cite this abstract in AMA style:

Veckalns I, Mihailova A. Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/interleukin-6-concentration-in-synovial-fluid-and-its-clinical-significance/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-6-concentration-in-synovial-fluid-and-its-clinical-significance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology